YOLFTbeta
Abcellera Biologics Inc

Abcellera Biologics Inc

ABCL · NASDAQ · Healthcare / Biotechnology

11.49USD-0.13 (-1.12%)

Price History

Full chart

Market Stats

Previous Close11.62
Open11.75
Day Range11.06 – 11.83
52-Week Range2.75 – 13.18
Volume2.62M
Market Cap4.10B
P/E (TTM)0.00
Forward P/E27.55
EPS-0.55
Dividend Yield0.00%
Beta1.32
50-Day Avg9.57
200-Day Avg5.67

About

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Carl L.G. Hansen Ph.D.
  • Employees562
  • Headquarters150 W 4th Avenue, Vancouver, BC, Canada, V5Y 1G6, USA
  • Websitehttps://www.abcellera.com

Leadership

  • Dr. Carl L.G. Hansen Ph.D.CEO, President & Chairperson · b. 1975
  • Mr. Andrew Booth M.B.A.Chief Financial Officer · b. 1974
  • Dr. Veronique Lecault Ph.D.CTO & Director · b. 1985
  • Mr. Tryn T. Stimart Esq., J.D., M.Sc.Chief Legal Officer, Chief Compliance Officer, Corporate Secretary & Privacy Officer · b. 1970
  • Mr. Andrew Knowles M.Sc.Vice President of Operations
  • Marcie Thiessen CPA, CGASenior Director of Finance & Accounting
  • Mr. Martin Hogan M.Sc.Senior Director of Strategic Finance & IR
  • Ms. Tiffany Chiu B.Sc., Ph.D.Vice President of Communications
  • Caitlin Webster CIPD, M.Sc.Director of Talent Development
  • Mr. Murray McCutcheon Ph.D.Senior Vice President of Partnering

Financials

Income Statement

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue8.83M11.61M233.16M11.61M485.42M38.02M28.83M75.13M
Growth (%)-+31.49%+1907.88%-95.02%+4080.53%-92.17%-24.17%+160.56%
Cost of Revenue5.80M10.11M27.14M45.52M66.44M30.89M97.00M28.82M
Gross Profit8.83M11.61M206.01M11.61M418.99M38.02M28.83M46.31M
Gross Margin100.00%100.00%88.36%100.00%86.31%100.00%100.00%61.64%
Operating Expense9.58M15.73M49.98M15.73M202.48M275.23M343.60M263.41M
Operating Income-753.00K-4.12M156.03M-4.12M216.51M-237.21M-314.77M-217.10M
Operating Margin-8.53%-35.45%66.92%-35.46%44.60%-623.82%-1091.69%-288.98%
EBITDA1.44M-155.00K169.62M-154.61K260.17M-192.16M-204.15M-148.77M
EBITDA Margin16.29%-1.33%72.75%-1.33%53.60%-505.35%-708.04%-198.03%
Net Income309.00K-2.21M118.92M-2.21M158.52M-146.40M-162.86M-146.41M
Net Income Margin3.50%-19.04%51.00%-19.04%32.66%-385.00%-564.83%-194.88%
R&D5.80M10.11M29.39M62.06M107.88M175.66M167.26M186.83M
R&D as % of Total Revenue65.71%87.09%12.61%534.49%22.22%461.95%580.10%248.68%
Interest Expense212.00K209.00K6.51M209.20K4.04M---
Interest Expense % of Total Revenue2.40%1.80%2.79%1.80%0.83%---

Balance Sheet

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets21.49M23.49M1.01B1.32B1.54B1.49B1.36B1.36B
Total Liabilities9.88M13.24M175.03M292.84M307.63M335.78M304.47M390.05M
Total Equity11.61M10.25M830.51M1.03B1.23B1.15B1.06B966.90M
Cash10.44M7.55M594.12M476.14M386.54M133.32M156.32M128.51M
Total Debt3.44M6.89M6.78M40.06M82.26M77.38M65.36M143.22M
Net Debt-7.00M-662.00K-587.34M-436.08M-304.28M-55.94M-90.96M14.71M

Cash Flow

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow3.56M2.69M22.69M244.58M277.36M-43.88M-108.56M-131.29M
Investing Cash Flow-5.31M-5.78M-119.78M-332.25M-352.63M-221.11M121.41M87.75M
Financing Cash Flow12.19M195.00K683.65M-3.89M-1.63M10.36M12.77M14.08M
Capital Expenditure5.31M4.00M14.67M58.45M72.66M77.51M78.40M42.77M
Free Cash Flow-1.74M-1.30M8.02M186.13M204.70M-121.38M-186.95M-174.07M
Dividends Paid-14.16K------
FCF to OCF-48.86%-48.37%35.33%76.10%73.80%276.65%172.22%132.58%
Dividend Paid to FCF--1.09%------

Earnings

Report DateMar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 14, 2020Mar 29, 2021May 13, 2021Aug 12, 2021Nov 9, 2021Feb 24, 2022May 10, 2022Aug 9, 2022Nov 8, 2022Feb 21, 2023May 4, 2023Aug 3, 2023Nov 2, 2023Feb 20, 2024May 7, 2024Aug 6, 2024Nov 4, 2024Feb 18, 2025May 8, 2025Aug 7, 2025Nov 6, 2025Feb 24, 2026May 11, 2026Aug 5, 2026Nov 5, 2026
EPS Estimate0.000.000.000.000.000.00--0.020.610.380.09-0.060.190.42-0.020.05-0.01-0.13-0.12-0.13-0.12-0.16-0.14-0.13-0.15-0.14-0.17-0.16-0.14-0.20-0.17-0.18
EPS Actual-0.00-0.000.00-0.010.010.01-0.01-0.040.440.37-0.01-0.080.190.54-0.020.08-0.10-0.14-0.11-0.10-0.16-0.14-0.13-0.17-0.12-0.15-0.12-0.19-0.03-0.14-0.18-
Surprise--------100.00%-27.87%-2.63%-111.11%-33.33%0.00%28.57%0.00%60.00%-900.00%-7.69%8.33%23.08%-33.33%12.50%7.14%-30.77%18.42%-7.14%29.41%-18.75%79.17%30.00%-5.88%-
Timing-------After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap4.10B
Enterprise Value3.59B
Trailing P/E0.00
Forward P/E27.55
Price / Sales61.95
Price / Book4.45
EPS-0.55
Book Value2.92
Revenue (TTM)66.17M
Gross Profit (TTM)-131.60M
EBITDA-199.96M
Profit Margin-248.84%
Operating Margin-1550.05%
Return on Equity-17.30%
Return on Assets-10.39%
Shares Outstanding324.05M
Shares Float209.04M
Beta1.32
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 9 analystsTarget 16.67
  • Strong Buy
    6
  • Buy
    2
  • Hold
    1

Ownership Breakdown

Institutions
36.70%
Insiders
21.74%
Retail / Other
41.56%

Top Institutional Holders

  • Baker Bros Advisors LP
    30.28M9.34%
  • Capital World Investors
    13.59M4.19%
  • Two Sigma Investments LLC
    10.44M3.22%
  • TD Waterhouse Canada Inc
    9.56M2.95%
  • UBS Asset Mgmt Americas Inc
    7.58M2.34%
  • UBS Group AG
    4.21M1.30%
  • ArrowMark Colorado Holdings, LLC (ArrowMark Partners)
    4.11M1.27%
  • BlackRock Inc
    4.04M1.25%
  • Driehaus Capital Management LLC
    4.02M1.24%
  • The Goldman Sachs Group Inc
    3.75M1.16%
  • Bank of America Corp
    3.00M0.93%
  • Jefferies Financial Group Inc
    2.75M0.85%
  • Alyeska Investment Group, L.P.
    2.59M0.80%
  • Morgan Stanley - Brokerage Accounts
    2.22M0.69%
  • Tudor Investment Corp Et AL
    2.06M0.64%
  • Citadel Advisors Llc
    1.59M0.49%

Top Fund Holders

  • American Funds SMALLCAP World A
    13.23M4.08%
  • ACATIS Datini Valueflex Fonds A
    1.86M0.57%
  • UBS Lux Dgtl Hlth Eq Fd seeding P acc
    1.76M0.54%
  • iShares Biotechnology ETF
    1.76M0.54%